TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-17

Archived explainer. For the current picture see today's CGON page.

Why Is CG ONCOLOGY INC (CGON) Stock Down Today?

By the Top Tier Newswire AI Desk · November 17, 2026 at 9:45 AM ET · reviewed against 21 wire stories

CG ONCOLOGY INC (CGON) is down -8.16% in the latest session. Our newswire has captured 21 stories on CGON across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

CG Oncology (CGON) shares fell 8.16% to $77.86, driven by a mix of positive trial data and a new downgrade from RBC Capital. The stock had previously surged 30.8% over the last eight sessions, reaching a 52-week high before the current pullback.

What Happened

The primary catalyst for the session was the release of positive topline results from the Phase 3 PIVOT-006 trial. Following the data, several major banks adjusted their valuations. Truist raised its price target to $100 from $85, while JPMorgan lifted its target to $113 from $96. Wedbush and HC Wainwright & Co. also raised their targets to $91 and $115, respectively. Despite these upgrades, RBC Capital downgraded the stock to Sector Perform from Outperform. The company also reported third-quarter 2026 financial results, noting revenue growth of 183.6% on a trailing twelve-month basis.

What The Data Shows

The stock opened at $83.21, a 1.9% gap down from the prior close of $84.78. It traded as low as $77.11 at 9:45 AM ET before stabilizing near $77.68. Volume stood at 0.2 million shares, which is 0.2 times the three-month daily average. The company has a market capitalization of $6.6 billion and remains unprofitable with a trailing twelve-month EPS of -$2.78. Its beta is 0.35, and the 52-week range spans $37.01 to $93.95. Recent SEC filings show two sales by director Leonard E. Post totaling $135,000, with no buys in the last 90 days.

What To Watch

Analysts continue to debate the long-term valuation following the trial data. Investors should monitor the breadth of coverage, as 21 stories from nine sources were published in the last 36 hours. The upcoming earnings date is not specified in the current data set.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

CGON by the numbers

Last: $77.86Session: -8.16%7 sessions: +3.88%Coverage: 21 stories / 9 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $6.6B52w: $37.01 to $93.95
CGON · Nov 17 session (5-min) · -6.82% vs prior close · updated 8:46 PM ET
$73.00$79.22$85.45prev close $84.78$79.007:30 AM9:55 AM12:20 PM2:45 PM5:10 PM7:30 AM · $83.217:50 AM · $83.438:20 AM · $84.108:25 AM · $83.909:15 AM · $84.769:25 AM · $82.989:30 AM · $80.399:35 AM · $80.959:40 AM · $77.869:45 AM · $76.349:50 AM · $75.089:55 AM · $73.6710:00 AM · $74.7810:05 AM · $77.1010:10 AM · $76.5410:15 AM · $76.6410:20 AM · $77.6310:25 AM · $78.7210:30 AM · $78.4010:35 AM · $78.0310:40 AM · $77.9410:45 AM · $77.4210:50 AM · $77.2810:55 AM · $76.7811:00 AM · $76.3211:05 AM · $77.3311:10 AM · $77.2911:15 AM · $77.6511:20 AM · $77.0411:25 AM · $76.7911:30 AM · $76.3811:35 AM · $76.4011:40 AM · $76.6011:45 AM · $76.5511:50 AM · $76.3311:55 AM · $76.5912:00 PM · $76.8412:05 PM · $77.6812:10 PM · $78.1612:15 PM · $79.7012:20 PM · $79.6112:25 PM · $79.8412:30 PM · $79.1612:35 PM · $79.4812:40 PM · $79.6212:45 PM · $79.3112:50 PM · $79.3912:55 PM · $78.621:00 PM · $79.091:05 PM · $79.151:10 PM · $79.491:15 PM · $79.591:20 PM · $79.611:25 PM · $79.781:30 PM · $79.771:35 PM · $79.791:40 PM · $79.231:45 PM · $79.561:50 PM · $79.281:55 PM · $79.502:00 PM · $79.082:05 PM · $79.082:10 PM · $79.482:15 PM · $79.122:20 PM · $79.132:25 PM · $79.052:30 PM · $79.082:35 PM · $78.702:40 PM · $78.702:45 PM · $78.462:50 PM · $78.532:55 PM · $78.983:00 PM · $78.713:05 PM · $78.283:10 PM · $78.163:15 PM · $78.173:20 PM · $78.973:25 PM · $78.993:30 PM · $79.273:35 PM · $79.293:40 PM · $79.023:45 PM · $78.813:50 PM · $79.033:55 PM · $78.924:00 PM · $78.944:20 PM · $79.004:25 PM · $79.005:10 PM · $79.00
AI sentiment, last 36h · averaged over 21 stories · 63/100 bullish
AI sentiment 63/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishThe Fly · sentiment 34 · CG Oncology downgraded to Sector Perform from Outperform at RBC CapitalThe Fly · 34CG Oncology downgraded to Sector Perform from Outperform at RBC CapitalThe Fly · sentiment 64 · CG Oncology price target raised to $113 from $96 at JPMorganThe Fly · 64CG Oncology price target raised to $113 from $96 at JPMorganInvesting.com Analyst Ratings · sentiment 64 · JPMorgan raises CG Oncology stock price target on trial dataInvesting.com Analyst Ratings · 64JPMorgan raises CG Oncology stock price target on trial dataThe Fly · sentiment 64 · CG Oncology price target raised to $91 from $84 at WedbushThe Fly · 64CG Oncology price target raised to $91 from $84 at WedbushInvesting.com Analyst Ratings · sentiment 64 · Truist raises CG Oncology stock price target on trial resultsInvesting.com Analyst Ratings · 64Truist raises CG Oncology stock price target on trial resultsGuruFocus · sentiment 63 · CGON Maintained by HC Wainwright & Co. -- Price Target Raised to $115GuruFocus · 63CGON Maintained by HC Wainwright & Co. -- Price Target Raised to $115The Fly · sentiment 64 · CG Oncology price target raised to $100 from $85 at TruistThe Fly · 64CG Oncology price target raised to $100 from $85 at TruistGuruFocus · sentiment 63 · CGON Maintained by Wedbush -- Price Target Raised to $91.00GuruFocus · 63CGON Maintained by Wedbush -- Price Target Raised to $91.00
3d agoGuruFocusBULLISH 63Analyst

CGON Maintained by Wedbush -- Price Target Raised to $91.00

3d agoThe FlyBULLISH 64Analyst

CG Oncology price target raised to $100 from $85 at Truist

3d agoGuruFocusBULLISH 63Analyst

CGON Maintained by HC Wainwright & Co. -- Price Target Raised to $115

3d agoInvesting.com Analyst RatingsBULLISH 64Analyst

Truist raises CG Oncology stock price target on trial results

Truist raises CG Oncology stock price target on trial results

3d agoThe FlyBULLISH 64Analyst

CG Oncology price target raised to $91 from $84 at Wedbush

3d agoInvesting.com Analyst RatingsBULLISH 64Analyst

JPMorgan raises CG Oncology stock price target on trial data

JPMorgan raises CG Oncology stock price target on trial data

3d agoThe FlyBULLISH 64Analyst

CG Oncology price target raised to $113 from $96 at JPMorgan

3d agoThe FlyBEARISH 34Analyst

CG Oncology downgraded to Sector Perform from Outperform at RBC Capital

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on CGON: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier CGON move explainers: 2026-11-17 · 2026-11-16